Levosulpiride Injection: Uses, Doses, and Contraindications
Levosulpiride injection is primarily used for managing delirium with agitation in palliative care settings and as a second-line treatment for functional dyspepsia, with typical dosing of 12.5-25 mg subcutaneously every 2 hours as needed for delirium, or 25 mg three times daily for dyspepsia.
Primary Indications
Delirium Management (Palliative Care Setting)
Levomepromazine (levosulpiride) is specifically recommended for delirium in patients unable to swallow 1, 2. This represents its most evidence-based indication from guideline sources.
Dosing for delirium:
- Starting dose: 12.5-25 mg subcutaneously as initial dose 2
- PRN dosing: 12.5-25 mg subcutaneously every 2 hours as needed 2
- Elderly patients: Use reduced doses of 6.25-12.5 mg 2
- Maintenance: 50-200 mg subcutaneously over 24 hours via continuous infusion 1, 2
- Important: Doses >100 mg over 24 hours require specialist supervision 1, 2
Functional Dyspepsia (Second-Line Treatment)
Levosulpiride 25 mg three times daily may be used as a second-line treatment for functional dyspepsia when first-line therapies (PPIs, H2-blockers, prokinetics) have failed 3. This requires careful explanation of rationale and counseling about side effects.
Gastroparesis (Off-Label)
Levosulpiride showed significant improvement in diabetic gastroparesis symptoms and gastric emptying in controlled trials 4, though specific dosing protocols are not standardized in guidelines.
Postoperative Nausea and Vomiting
Levosulpiride 25 mg intravenously given within 30 minutes of anesthesia induction has demonstrated efficacy comparable to ramosetron for PONV prevention in laparoscopic surgery 5.
Pharmacokinetic Considerations
Critical absorption differences:
- Oral bioavailability: Only 23.4% 6
- Intramuscular bioavailability: 96.8% 6
- Time to steady state: 4 days with oral dosing, 2 days with IM dosing 6
This poor oral bioavailability explains why injectable formulations are preferred for acute symptom control, as oral administration results in delayed clinical efficacy 6.
Contraindications and Precautions
Absolute Contraindications
- Parkinson's disease - risk of severe extrapyramidal symptoms 2
- Dementia with Lewy bodies - risk of severe extrapyramidal symptoms 2
- Pheochromocytoma - dopamine antagonist effects
- Prolactin-dependent tumors
Major Warnings and Side Effects
Extrapyramidal symptoms (EPSEs): Common and potentially severe 2, 7
- Monitor closely for dystonia, akathisia, parkinsonism
- More than 50% of participants experienced adverse events in pharmacokinetic studies 6
Cardiovascular effects:
- Orthostatic hypotension - particularly concerning 2
- QTc prolongation - requires ECG monitoring in high-risk patients
- Use with extreme caution in elderly patients
Other significant effects:
- Sedation - marked sedating properties 2
- Anticholinergic effects 2
- Paradoxical agitation - may worsen symptoms 2
- Local irritation at subcutaneous injection site 2
- Hyperprolactinemia - galactorrhea, amenorrhea, gynecomastia
Special Populations
Elderly/frail patients:
- Start with 2.5 mg and titrate gradually 2
- Higher risk of orthostatic hypotension and falls
- Increased sensitivity to extrapyramidal effects
Renal/hepatic impairment:
- Use with caution; dose reduction may be necessary
- Specific dosing adjustments not well-established in guidelines
Pregnancy/lactation:
- Avoid unless absolutely necessary
- Crosses into breast milk
Common Pitfalls to Avoid
Do not use oral supplementation expecting rapid effect - the 23.4% bioavailability means delayed onset 6
Do not combine with benzodiazepines without extreme caution - risk of oversedation and respiratory depression 2
Do not exceed 100 mg/24 hours without specialist supervision 1, 2
Do not use in patients already on antipsychotics without careful consideration of cumulative dopamine blockade
Monitor for subcutaneous injection site irritation - rotate sites regularly 2
Route-Specific Dosing Summary
Subcutaneous (preferred for acute delirium):
- Acute: 12.5-25 mg every 2 hours PRN
- Continuous infusion: 50-200 mg over 24 hours
Intramuscular:
- 25 mg for PONV prevention (single dose)
- Similar dosing to subcutaneous for other indications
Oral (for chronic conditions only):
- Dyspepsia: 25 mg three times daily
- Expect delayed therapeutic effect due to poor absorption
Intravenous:
- 25 mg for PONV (within 30 minutes of induction)
- Not routinely recommended for other indications
Drug Interactions
Avoid or use extreme caution with:
- Other antipsychotics (additive dopamine blockade)
- Benzodiazepines (respiratory depression risk) 2
- QTc-prolonging medications
- Anticholinergic agents (additive effects)
- CNS depressants (additive sedation)